Biofrontera AG (BFRA) EPS Estimated At $-0.09

August 13, 2018 - By Nadine Davis

Analysts expect Biofrontera AG (NASDAQ:BFRA) to report $-0.09 EPS on August, 30.After having $-0.20 EPS previously, Biofrontera AG’s analysts see -55.00 % EPS growth. The stock decreased 0.38% or $0.05 during the last trading session, reaching $13.25. About 3,598 shares traded. Biofrontera AG (NASDAQ:BFRA) has 0.00% since August 13, 2017 and is . It has underperformed by 12.57% the S&P500.

Biofrontera AG, a biopharmaceutical company, primarily focuses on the discovery, development, and distribution of dermatological drugs and dermatologically tested cosmetics for the treatment and care of diseased skin. The company has market cap of $309.77 million. The Company’s products include Ameluz, a prescription drug for the treatment of actinic keratosis, a superficial skin cancer; BF-RhodoLED, a lamp for photodynamic therapy with LEDs emitting red light at an average wavelength of 635 nm; Belixos, a cream with herbal ingredients for the care of inflamed, itchy, and flaky skin, such as localized itching, atopic dermatitis, or psoriasis; Belixos LIQUID to treat itching and scaliness, and restore the scalp's natural balance; Belixos GEL for use on inflamed and reddened skin, and skin prone to impurities; belixos To Go for relief from itchiness, insect bites, and minor burns; and Belixos PROTECT for the needs of sun-damaged skin. It currently has negative earnings. The firm is also developing BF-derm1, which is in Phase II clinical trial for the treatment of chronic and antihistamine-refractory urticaria; and BF-1, a serotonin receptor antagonist that is in Phase I clinical trial to treat migraine prophylaxis.

Another recent and important Biofrontera AG (NASDAQ:BFRA) news was published by Seekingalpha.com which published an article titled: “Stocks To Watch: Any Privacy For Tesla?” on August 11, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.